A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

Elotuzumab, an immunostimulatory SLAMF7‐targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3‐h infusion), combined with lenalidomide and dexa...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of hematology 2017-05, Vol.92 (5), p.460-466
Hauptverfasser:	Berenson, James, Manges, Robert, Badarinath, Suprith, Cartmell, Alan, McIntyre, Kristi, Lyons, Roger, Harb, Wael, Mohamed, Hesham, Nourbakhsh, Ali, Rifkin, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Dexamethasone - administration & dosage Drug Administration Schedule Hematology Humans Multiple myeloma Multiple Myeloma - drug therapy Patient Safety Premedication - methods Thalidomide - administration & dosage Thalidomide - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!